2013 saw the Swedish Biotech Industry raising a significantly smaller venture financing amount than in the year before (USD 27m compared to USD 127m in 2012). During the same period the number of companies achieving an IPO exit doubled.
The number of biotech products in Phase I of development remained stable compared to last year, while products in the pre-clinical phase and clinical phases II and III were reduced by 20, 23 and 19% respectively.
Looking for your next Biotech or Medtech partner?
Use Biotechgate to identify new leads, licensing opportunities and management details.